# Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06950086/  
OnCo record `nct06950086` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TYK-00540 in HR-positive / HER2-negative breast cancer, run by TYK Medicines, Inc, now recruiting.

## Summary

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06950086 by TYK Medicines, Inc, with 180 participants planned, started 2024-01-02 and due to reach its primary completion in 2026-09. Interventions recorded: TYK-00540.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06950086
- Phase: 1/2
- Setting: A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of the CDK2/4/6 Inhibitor TYK-00540 Tablets in Patients With Advanced Solid Tumors
- Sponsor: TYK Medicines, Inc
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06950086: https://clinicaltrials.gov/study/NCT06950086

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)

---
JSON: https://onco.cc/api/v1/entities/nct06950086.json